Loading
ITGB3 (Integrin beta-3) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor (VWF). Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognise the sequence R-G-D in a wide array of ligands.
Open Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes clinical 0.50, affected pathway 0.97, literature 0.97, genetic association 0.00, animal model 0.52).
In plain words · ITGB3 (Integrin beta-3) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
ITGB3 (Integrin beta-3) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor (VWF).
No product in this corpus aims at ITGB3 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ITGB3: RNA tissue enhanced (blood vessel 38 nTPM, thyroid gland 53 nTPM); blood lineage lineage enriched (granulocytes 6 nTPM); high antibody staining in 1 normal tissue; highest cancer staining renal cancer (1 of 12 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas ITGB3 tissue; Open Targets ENSG00000259207 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: Fitzgerald L.A. et al, J. Biol. Chem, 1987, "Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity to 'integrin'". Source.
Sources: HGNC HGNC:6156 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P05106 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000259207 (association with cancer (MONDO_0004992) 0.68; (GraphQL API, CC0))
Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor (VWF). Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognise the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognises the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Location: Cell membrane; Cell projection, lamellipodium membrane; Cell junction, focal adhesion; Postsynaptic cell membrane (UniProt). Locus 17q21.32 (HGNC).
RNA: tissue enhanced (blood vessel 38 nTPM, thyroid gland 53 nTPM), detected in many normal tissues. Blood: lineage enriched (granulocytes 6 nTPM).
RNA cancer enhanced: Skin Cutaneous Melanoma 43 pTPM, Thyroid Carcinoma 55 pTPM.
Medium only: endometrial cancer, liver cancer.
HPA ITGB3 tissue · HPA ITGB3 pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ITGB3" OR ABSTRACT:"ITGB3" OR TITLE:"integrin subunit beta 3" OR ABSTRACT:"integrin subunit beta 3" OR TITLE:"Integrin beta-3" OR ABSTRACT:"Integrin beta-3" OR TITLE:"CD61" OR ABSTRACT:"CD61" OR TITLE:"GPIIIa" OR ABSTRACT:"GPIIIa" OR TITLE:"GP3A" OR ABSTRACT:"GP3A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ITGB3, not a curated reading list.